Research programme: nonsteroidal glucocorticoid receptor agonists - Boehringer Ingelheim
Latest Information Update: 01 Mar 2011
At a glance
- Originator Boehringer Ingelheim
- Class Aza compounds; Indoles; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Inflammation; Rheumatoid arthritis